Paritaprevir (ABT-450) is primarily used in the treatment of chronic hepatitis C virus (HCV) infection. It functions as a protease inhibitor, specifically targeting the NS3/4A protease enzyme, which is essential for viral replication. By inhibiting this enzyme, it prevents the virus from multiplying and spreading in the body.

It is often used in combination with other antiviral agents, such as ombitasvir and dasabuvir, as part of a multi-drug regimen to enhance efficacy and reduce the risk of resistance. This combination therapy has shown significant success in achieving sustained virologic response (SVR), effectively curing the infection in many patients.

Paritaprevir is particularly effective against HCV genotypes 1 and 4, making it a valuable option for patients with these specific strains. Its use has revolutionized HCV treatment, offering a higher cure rate, shorter treatment duration, and fewer side effects compared to older therapies.

It is administered orally, making it convenient for patients, and is typically prescribed after careful evaluation of the patient’s medical history and HCV genotype. Its role in modern antiviral therapy has greatly improved outcomes for individuals living with chronic hepatitis C.